查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000454

2034年生成式人工智慧驅動的分子創建和應用轉型市場預測：按產品、組件、技術、應用、最終用戶和地區分類的全球分析

Generative AI Molecule Discovery & Repurposing Market Forecasts to 2034 - Global Analysis By Product, By Component, By Technology, By Application, By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生成式人工智慧驅動的分子藥物發現和適應症擴展市場預計將在 2026 年達到 46 億美元，在預測期內以 30% 的複合年成長率成長，到 2034 年達到 495 億美元。

生成式人工智慧驅動的分子藥物發現和仿單標示外用藥包括利用人工智慧模型設計新化合物並識別現有藥物的新治療用途。這些人工智慧系統分析大規模生物和化學資料集，產生具有最佳化特性的潛在候選藥物。它們可以模擬分子間相互作用並預測療效，從而加速藥物發現的早期階段。透過縮短研發時間和降低開發成本，生成式人工智慧幫助製藥公司更有效率地識別有前景的治療方法，同時拓展已通過核准藥物用於治療新疾病的仿單標示外用途的機會。

人工智慧加速藥物研發。

人工智慧演算法能夠快速識別新型分子並預測治療效果，從而顯著降低傳統藥物研發所需的時間和成本。製藥和生物技術公司正擴大採用人工智慧平台來提高研發效率。人工智慧開發商與研究機構之間的合作進一步推動了這一趨勢。這種技術發展勢頭持續推動著全球市場的成長。

高昂的運算基礎設施成本

生成式人工智慧平台需要先進的硬體、雲端運算資源和專業知識。中小企業和Start-Ups往往難以承擔這些投資。持續的維護和資料管理也會推高營運成本。新興地區基礎設施匱乏，難以負擔，阻礙了人工智慧平台的普及。這些財務障礙持續阻礙人工智慧平台向更廣泛的市場滲透。

將現有藥物重新用於新的適應症

生成式人工智慧可以分析分子結構，並預測已通過核准藥物的新用途。與研發新藥相比，這種方法可以縮短研發時間並減少監管障礙。製藥公司正利用人工智慧拓展產品平臺信譽度。預計這一機會將推動該行業的創新和成本效益。

人工智慧設計藥物的監管不確定性

在許多司法管轄區，人工智慧設計分子的核准流程仍然不明朗。缺乏標準化的框架給商業化帶來了挑戰。法規核准的延誤阻礙了對人工智慧驅動藥物研發的投資。人們對人工智慧模型的透明度和可解釋性的擔憂進一步加劇了合規性的複雜性。這種不確定性仍是生成式人工智慧在製藥領域規模化應用的一大挑戰。

新冠疫情的影響：

新冠疫情加速了人們對人工智慧驅動藥物研發的興趣。對治療方法和疫苗的迫切需求凸顯了加速研發進程的必要性。生成式人工智慧平台被用來識別有前景的分子並拓展現有藥物的適應症。生物技術和人工智慧Start-Ups的資金投入增加，推動了創新。遠端協作工具在疫情封鎖期間為全球研究活動提供了支援。總而言之，新冠疫情再次印證了人工智慧在建構穩健的藥物研發流程的重要性。

在預測期內，軟體平台細分市場預計將佔據最大佔有率。

隨著人工智慧工具成為分子建構的基礎，預計在預測期內，軟體平台領域將佔據最大的市場佔有率。製藥和生物技術公司依賴先進的平台進行預測建模和分子設計。演算法的持續創新正在提高準確性和效率。雲端解決方案正在擴大跨區域的可及性。對整合平台日益成長的需求進一步鞏固了該領域的領先地位。

在預測期內，生技公司板塊預計將呈現最高的複合年成長率。

在預測期內，生技公司板塊預計將呈現最高的成長率，這主要得益於其在採用人工智慧驅動解決方案方面的敏捷性。生物技術公司正擴大利用生成式人工智慧來加速藥物研發流程並促進分子重定位。創業投資的增加正在推動Start-Ups採用人工智慧技術。與人工智慧開發商和製藥公司的合作正在推動創新。對精準醫療日益成長的需求也進一步促進了該板塊的發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健基礎設施和強大的研發投入。美國在人工智慧藥物研發領域的應用方面處於領先地位，成熟的製藥和生物技術公司正在推動創新。法律規範和資金籌措進一步舉措了商業化進程。強大的創業投資正在加速Start-Ups的成長。與學術機構的合作則有助於提升信譽度和推廣應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健和生物技術領域的快速發展。中國、印度和日本等國正加速採用人工智慧驅動的藥物研發平台。政府主導的舉措和資助計畫正在推動創新。本土Start-Ups正以經濟高效的解決方案進入市場，從而擴大了醫療服務的可近性。不斷擴展的數位基礎設施和雲端運算也為進一步成長提供了支援。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：利用生成式人工智慧進行分子創建和應用轉化的全球市場：按產品分類

  • 人工智慧驅動的藥物發現平台
  • 分子合成軟體
  • 化學回收引擎
  • 虛擬篩檢平台
  • 其他產品

第6章：利用生成式人工智慧進行分子創建和應用轉換的全球市場：按組件分類

  • 軟體平台
  • 人工智慧演算法和模型
  • 資料庫
  • 雲端基礎設施
  • 計算化學工具
  • 其他規則

第7章：利用生成式人工智慧進行分子創建和應用轉換的全球市場：按技術分類

  • 深度學習
  • 變壓器模型
  • 圖神經網路
  • 強化學習
  • 其他技術

第8章：利用生成式人工智慧進行分子創建和應用轉換的全球市場：按應用領域分類

  • 腫瘤藥物研發
  • 罕見疾病治療方法的研究
  • 感染疾病調查
  • 中樞神經系統（CNS）藥物發現
  • 免疫學/炎症
  • 其他用途

第9章：基於生成式人工智慧的分子創建和應用轉化全球市場：按最終用戶分類

  • 製藥公司
  • 生技公司
  • CRO
  • 學術研究機構
  • 其他最終用戶

第10章：全球分子創建及基於生成式人工智慧的應用轉換市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Insilico Medicine
  • Exscientia plc
  • BenevolentAI
  • Recursion Pharmaceuticals, Inc.
  • Schrodinger, Inc.
  • Atomwise, Inc.
  • XtalPi Inc.
  • Generate Biomedicines
  • Deep Genomics Inc.
  • Relay Therapeutics, Inc.
  • IBM Corporation
  • Alphabet Inc.
  • Microsoft Corporation
  • NVIDIA Corporation
  • Absci Corporation
Product Code: SMRC34510

According to Stratistics MRC, the Global Generative AI Molecule Discovery & Repurposing Market is accounted for $4.6 billion in 2026 and is expected to reach $49.5 billion by 2034 growing at a CAGR of 30% during the forecast period. Generative AI Molecule Discovery & Repurposing involves the use of artificial intelligence models to design new chemical compounds or identify new therapeutic uses for existing drugs. These AI systems analyze large biological and chemical datasets to generate potential drug candidates with optimized properties. They can simulate molecular interactions, predict efficacy, and accelerate early-stage drug discovery. By reducing research timelines and development costs, generative AI helps pharmaceutical companies identify promising treatments more efficiently while expanding opportunities for repurposing approved drugs for new diseases.

Market Dynamics:

Driver:

Accelerating drug discovery with AI

AI algorithms enable rapid identification of novel molecules and predictive modeling of therapeutic outcomes. This significantly reduces the time and cost associated with traditional drug development. Pharmaceutical and biotech firms are increasingly adopting AI platforms to enhance R&D efficiency. Partnerships between AI developers and research institutions are further strengthening adoption. This technological momentum continues to propel global market growth.

Restraint:

High computational infrastructure costs

Generative AI platforms require advanced hardware, cloud computing resources, and specialized expertise. Smaller firms and startups often struggle to afford these investments. Ongoing maintenance and data management add to operational expenses. Limited access to affordable infrastructure slows adoption in emerging regions. These financial barriers continue to restrict broader market penetration.

Opportunity:

Repurposing existing drugs for new indications

Generative AI can analyze molecular structures and predict alternative applications for approved drugs. This approach reduces development timelines and regulatory hurdles compared to novel drug creation. Pharmaceutical firms are leveraging AI-driven repurposing to expand product pipelines. Collaborations with healthcare providers and research institutions are enhancing credibility. This opportunity is expected to drive innovation and cost efficiency in the sector.

Threat:

Regulatory uncertainty for AI-designed drugs

Approval processes for AI-designed molecules remain unclear in many jurisdictions. Lack of standardized frameworks creates challenges for commercialization. Regulatory delays discourage investment in AI-driven drug discovery. Concerns about transparency and explainability of AI models further complicate compliance. This uncertainty continues to challenge the scalability of generative AI in pharmaceuticals.

Covid-19 Impact:

The Covid-19 pandemic accelerated interest in AI-driven drug discovery. Urgent demand for treatments and vaccines highlighted the need for faster R&D processes. Generative AI platforms were leveraged to identify potential molecules and repurpose existing drugs. Increased funding for biotech and AI startups boosted innovation. Remote collaboration tools supported global research efforts during lockdowns. Overall, Covid-19 reinforced the relevance of AI in building resilient drug discovery pipelines.

The software platforms segment is expected to be the largest during the forecast period

The software platforms segment is expected to account for the largest market share during the forecast period as AI-driven tools form the backbone of molecule discovery. Pharmaceutical and biotech firms rely on advanced platforms for predictive modeling and molecular design. Continuous innovation in algorithms enhances accuracy and efficiency. Cloud-based solutions are expanding accessibility across regions. Rising demand for integrated platforms further strengthens this segment's dominance.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology companies segment is predicted to witness the highest growth rate due to their agility in adopting AI-driven solutions. Biotech firms are increasingly leveraging generative AI to accelerate drug pipelines and repurpose molecules. Rising venture capital investments are fueling adoption among startups. Collaborations with AI developers and pharmaceutical firms are driving innovation. Growing demand for precision medicine is further boosting this segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and strong R&D investments. The U.S. leads in AI adoption for drug discovery, with established pharmaceutical and biotech firms driving innovation. Regulatory frameworks and funding initiatives further support commercialization. Strong venture capital presence accelerates startup growth. Academic collaborations enhance credibility and adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid advancements in healthcare and biotechnology. Countries such as China, India, and Japan are witnessing increased adoption of AI-driven drug discovery platforms. Government-backed initiatives and funding programs are boosting innovation. Local startups are entering the market with cost-effective solutions, expanding accessibility. Expansion of digital infrastructure and cloud computing is further supporting growth.

Key players in the market

Some of the key players in Generative AI Molecule Discovery & Repurposing Market include Insilico Medicine, Exscientia plc, BenevolentAI, Recursion Pharmaceuticals, Inc., Schrodinger, Inc., Atomwise, Inc., XtalPi Inc., Generate Biomedicines, Deep Genomics Inc., Relay Therapeutics, Inc., IBM Corporation, Alphabet Inc., Microsoft Corporation, NVIDIA Corporation and Absci Corporation.

Key Developments:

In January 2026, Insilico launched the Science MMAI Gym, a new domain-specific training environment designed to transform general-purpose Large Language Models (LLMs) into high-performance engines for pharmaceutical-grade drug discovery tasks.

In February 2024, Exscientia signed a collaboration worth up to $674 million with the German Merck to discover novel small-molecule candidates across oncology, neurology, and immunology. The deal included a $20 million upfront payment for three initial research programs.

Products Covered:

  • AI-Driven Drug Design Platforms
  • Molecule Generation Software
  • Drug Repurposing Engines
  • Virtual Screening Platforms
  • Other Products

Components Covered:

  • Software Platforms
  • AI Algorithms & Models
  • Data Libraries
  • Cloud Infrastructure
  • Computational Chemistry Tools
  • Other Components

Technologies Covered:

  • Deep Learning
  • Transformer Models
  • Graph Neural Networks
  • Reinforcement Learning
  • Other Technologies

Applications Covered:

  • Oncology Drug Discovery
  • Rare Disease Drug Development
  • Infectious Disease Research
  • CNS Drug Discovery
  • Immunology & Inflammation
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • CROs
  • Academic Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Generative AI Molecule Discovery & Repurposing Market, By Product

  • 5.1 AI-Driven Drug Design Platforms
  • 5.2 Molecule Generation Software
  • 5.3 Drug Repurposing Engines
  • 5.4 Virtual Screening Platforms
  • 5.5 Other Products

6 Global Generative AI Molecule Discovery & Repurposing Market, By Component

  • 6.1 Software Platforms
  • 6.2 AI Algorithms & Models
  • 6.3 Data Libraries
  • 6.4 Cloud Infrastructure
  • 6.5 Computational Chemistry Tools
  • 6.6 Other Components

7 Global Generative AI Molecule Discovery & Repurposing Market, By Technology

  • 7.1 Deep Learning
  • 7.2 Transformer Models
  • 7.3 Graph Neural Networks
  • 7.4 Reinforcement Learning
  • 7.5 Other Technologies

8 Global Generative AI Molecule Discovery & Repurposing Market, By Application

  • 8.1 Oncology Drug Discovery
  • 8.2 Rare Disease Drug Development
  • 8.3 Infectious Disease Research
  • 8.4 CNS Drug Discovery
  • 8.5 Immunology & Inflammation
  • 8.6 Other Applications

9 Global Generative AI Molecule Discovery & Repurposing Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Biotechnology Companies
  • 9.3 CROs
  • 9.4 Academic Research Institutes
  • 9.5 Other End Users

10 Global Generative AI Molecule Discovery & Repurposing Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Insilico Medicine
  • 13.2 Exscientia plc
  • 13.3 BenevolentAI
  • 13.4 Recursion Pharmaceuticals, Inc.
  • 13.5 Schrodinger, Inc.
  • 13.6 Atomwise, Inc.
  • 13.7 XtalPi Inc.
  • 13.8 Generate Biomedicines
  • 13.9 Deep Genomics Inc.
  • 13.10 Relay Therapeutics, Inc.
  • 13.11 IBM Corporation
  • 13.12 Alphabet Inc.
  • 13.13 Microsoft Corporation
  • 13.14 NVIDIA Corporation
  • 13.15 Absci Corporation

List of Tables

  • Table 1 Global Generative AI Molecule Discovery & Repurposing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Generative AI Molecule Discovery & Repurposing Market, By Product (2023-2034) ($MN)
  • Table 3 Global Generative AI Molecule Discovery & Repurposing Market, By AI-Driven Drug Design Platforms (2023-2034) ($MN)
  • Table 4 Global Generative AI Molecule Discovery & Repurposing Market, By Molecule Generation Software (2023-2034) ($MN)
  • Table 5 Global Generative AI Molecule Discovery & Repurposing Market, By Drug Repurposing Engines (2023-2034) ($MN)
  • Table 6 Global Generative AI Molecule Discovery & Repurposing Market, By Virtual Screening Platforms (2023-2034) ($MN)
  • Table 7 Global Generative AI Molecule Discovery & Repurposing Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Generative AI Molecule Discovery & Repurposing Market, By Component (2023-2034) ($MN)
  • Table 9 Global Generative AI Molecule Discovery & Repurposing Market, By Software Platforms (2023-2034) ($MN)
  • Table 10 Global Generative AI Molecule Discovery & Repurposing Market, By AI Algorithms & Models (2023-2034) ($MN)
  • Table 11 Global Generative AI Molecule Discovery & Repurposing Market, By Data Libraries (2023-2034) ($MN)
  • Table 12 Global Generative AI Molecule Discovery & Repurposing Market, By Cloud Infrastructure (2023-2034) ($MN)
  • Table 13 Global Generative AI Molecule Discovery & Repurposing Market, By Computational Chemistry Tools (2023-2034) ($MN)
  • Table 14 Global Generative AI Molecule Discovery & Repurposing Market, By Other Components (2023-2034) ($MN)
  • Table 15 Global Generative AI Molecule Discovery & Repurposing Market, By Technology (2023-2034) ($MN)
  • Table 16 Global Generative AI Molecule Discovery & Repurposing Market, By Deep Learning (2023-2034) ($MN)
  • Table 17 Global Generative AI Molecule Discovery & Repurposing Market, By Transformer Models (2023-2034) ($MN)
  • Table 18 Global Generative AI Molecule Discovery & Repurposing Market, By Graph Neural Networks (2023-2034) ($MN)
  • Table 19 Global Generative AI Molecule Discovery & Repurposing Market, By Reinforcement Learning (2023-2034) ($MN)
  • Table 20 Global Generative AI Molecule Discovery & Repurposing Market, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Generative AI Molecule Discovery & Repurposing Market, By Application (2023-2034) ($MN)
  • Table 22 Global Generative AI Molecule Discovery & Repurposing Market, By Oncology Drug Discovery (2023-2034) ($MN)
  • Table 23 Global Generative AI Molecule Discovery & Repurposing Market, By Rare Disease Drug Development (2023-2034) ($MN)
  • Table 24 Global Generative AI Molecule Discovery & Repurposing Market, By Infectious Disease Research (2023-2034) ($MN)
  • Table 25 Global Generative AI Molecule Discovery & Repurposing Market, By CNS Drug Discovery (2023-2034) ($MN)
  • Table 26 Global Generative AI Molecule Discovery & Repurposing Market, By Immunology & Inflammation (2023-2034) ($MN)
  • Table 27 Global Generative AI Molecule Discovery & Repurposing Market, By Other Applications (2023-2034) ($MN)
  • Table 28 Global Generative AI Molecule Discovery & Repurposing Market, By End User (2023-2034) ($MN)
  • Table 29 Global Generative AI Molecule Discovery & Repurposing Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 30 Global Generative AI Molecule Discovery & Repurposing Market, By Biotechnology Companies (2023-2034) ($MN)
  • Table 31 Global Generative AI Molecule Discovery & Repurposing Market, By CROs (2023-2034) ($MN)
  • Table 32 Global Generative AI Molecule Discovery & Repurposing Market, By Academic Research Institutes (2023-2034) ($MN)
  • Table 33 Global Generative AI Molecule Discovery & Repurposing Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.